In-depth profiles and analysis for 20,000 public companies. Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. On average, analysts forecast that ABBV's EPS will be $11.80 for 2023, with the lowest EPS . Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. What other stocks do shareholders of AbbVie own? As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. As I have mentioned in previous notes, however, the gains owe more to price hikes than sales volumes, and come 2023 and the LOE, even AbbVie admits the blow to revenues will be substantial. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. I wrote this article myself, and it expresses my own opinions. I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. The above table shows quarterly and annual product revenues going back to FY20, whilst the last 4 columns show revenue growth percentage between FY20 and FY21, then revenue growth between Q2'21 and Q2'22, the sequential (quarter on quarter) growth, followed by product sales as a percentage of revenues. The companys operations span 20 countries, treating more than 60 million people and 40 conditions annually. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. The ex-dividend date of this dividend is Thursday, April 13th. What is AbbVie's stock price forecast for 2023? The major market events for the week ahead right in your inbox. I wrote this article myself, and it expresses my own opinions. One share of ABBV stock can currently be purchased for approximately $156.06. Shares of ABBV stock can be purchased through any online brokerage account. Their combined revenues are expected to reach $7.5bn in 2022, and Gonzalez told the audience at JPM that: Skyrizi and Rinvoq are now on pace to deliver more than $17.5 billion in combined sales, risk adjusted sales in 2025, well above our previous expectations. In my opinion, based on the current portfolio, AbbVie shares look undervalued below $160, but the upside above that price is limited, unless management is able to commercialize more products between now and the end of the decade, in order to achieve what looks like a very ambitious goal in driving high-single-digit revenue growth in the second half of this decade. One of the few pain points AbbVie experienced during a year of portfolio wide growth in 2022 was the decline in the revenue contribution from Imbruvica, approved to treat various types of lymphoma. I am not receiving compensation for it (other than from Seeking Alpha). I have not managed to match management's ambitious high-single-digit growth figures from 2025 - 2023, despite anticipating 6% growth for nearly all products in that period. We now expect global sales for Skyrizi to reach more than $10 billion in 2025, an increase of $2.5 billion versus our previous guidance, reflecting higher performance across basically all of the indications. My detailed modeling suggests there is 15-20% upside to look forward to in the short term and that ABBV stock remains a solid long-term buy opportunity for investors. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. Investors are already flocking there for a chance at 1,000%+ returns. Please. We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. Ltd., AbbVie Overseas S. r.l., AbbVie Oy, AbbVie Participaes Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? Since then, however, the stock price has fallen 18% to. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. For the next eight years, the forecast is for Free Cash Flow to grow by . We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. (844) 978-6257. Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. American biopharmaceutical company Abbvie (ABBV) has surged nearly 13% year to date (YTD), and 35% year-over-year (YOY), as of 30 June. Their ABBV share price forecasts range from $140.00 to $200.00. I have been maintaining a revenue forecasting table for AbbVie's products which I have amended based on Q2'22 and H1'22 results, and the slightly downgraded guidance issued for 2022 - management now expects adjusted earnings per share ("EPS") of $13.78 - $13.98, representing growth of 17% at the midpoint. Since then, however, the stock price has fallen 18% to its current price of $142.6. Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. I also considered the long-term outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. The average price target represents a 6.33% change from the last price of $153.90. In February, a Phase 3 induction study saw positive top-line results. Remember that past performance is not a guarantee of future results and you should never invest more money than you can afford to lose. Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. This suggests a possible upside of 3.2% from the stock's current price. The average price target is $163.64 with a high forecast of $190.00 and a low forecast of $133.00. Zscaler, Inc Plummets, Is It Time To Buy The Dip? Not only do these companies pay handsome dividends, they typically grow revenues every year and generate wide profit margins which leads to share price upside. (AbbVie JPM Healthcare conference presentation). In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. These products are not suitable for everyone and you should therefore consider your objectives, financial situation, needs and experience with these products before investing in them. AbbVie has 5 focus areas for its research and products. Real-time analyst ratings, insider transactions, earnings data, and more. ABBV Stock 12 Months Forecast. Having so much debt in a prevailing inflationary environment is also unattractive. You should consider whether you understand how CFDs work and can afford the risks. AbbVie saw a increase in short interest in February. ABBV-916 is targeting Alzheimer's and it is an anti-amyloid antibody, with a similar mechanism of action ("MoA") to recently approved Leqembi, developed by Biogen (BIIB) / Eisai, and likely soon-to-be approved Donanemab, developed by Eli Lilly. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB With AbbVie seemingly very confident of approvals for all 3 of these drugs, and Gonzalez suggesting they could form the basis of a "$6 billion kind of franchise" I have modelled for such an outcome by 2030. Always conduct your own due diligence before investing. I'm on twitter @edmundingham. The next two approvals - for Navitoclax in Myelofibrosis and Teliso V in non squamous non-small cell lung cancer ("NSCLC") - are anticipated by management in 2024. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. As of February 15th, there was short interest totaling 11,710,000 shares, an increase of 13.7% from the January 31st total of 10,300,000 shares. View institutional ownership trends. 8.05% 1 dividend stock for a LIFETIME of income. See what's happening in the market right now with MarketBeat's real-time news feed. That makes companies like AbbVie generally very attractive to investors although it should be noted that AbbVie carries a very high level of debt which stood at >$60bn as of Q322 - more or less the amount the company paid to acquire Allergan. Abbvie stock price has put up an impressive performance in 2022. . First we can take a quick look at what a forward income statement for AbbVie might look like to 2030. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. Projections are based on making fundamental and technical studies of the ABBV stock price performance. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Read our dividend analysis for ABBV. I wrote this article myself, and it expresses my own opinions. As such I have downgraded my own growth expectations in the forecasting table above, reducing annual growth from 7.5%, to just 2.5%, after forecasting for $5bn revenues in FY22 - down 7.5% year-on-year. Drug development has not traditionally been one of AbbVie's strengths - it has not had to be - but we ought to see the positive results of heavy investment into the oncology pipeline over the next 5-7 years, and by 2030, I believe this division could account for >17% of AbbVie's total revenues. After 2022 Humira's row is shaded yellow to signify patent expiry. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. AbbVie has a P/B Ratio of 15.97. AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions) . For the next nine years, the forecast is for Revenue to grow by 3.57%. Receive ABBV Stock News and Ratings via Email. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. The median. There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. This indicates that AbbVie will be able to sustain or increase its dividend. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". See AbbVie Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. I write about Biotech, Pharma and Healthcare stocks and share investment tips. What intrigues here is the possibility of RGX-314, an anti-VEGF gene therapy that Gonzalez believes "has the potential to be a one-time treatment for wet AMD, diabetic retinopathy and other chronic retinal conditions". The material provided on this website is for information purposes only and should not be understood as an investment advice. As such, forecasting stock prices is more of an art than a science. The division delivered >$1.65bn in sales in Q2'22, up >15% year-on-year, and with Vraylar, Ubrelvy and possibly Qulipta all earmarked for blockbuster sales - $4bn in the case of Vraylar - my forecasting suggests this division could double in size by 2030, from ~$6.6bn revenues generated in FY22, to >$13.5bn by 2030. To be sure, AbbVie is modeling for a tough year in 2023 for the aesthetics market. Since its 2013 separation from Abbott Laboratories (ABT 1.78%), AbbVie's stock has grown more than 160%. Move your mouse over a quarter or year to see how estimates have changed over time. The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. That reflects uncertainty about what the future holds for AbbVie. What is the dividend yield for AbbVie? What is Richard A. Gonzalez's approval rating as AbbVie's CEO? The total revenue in 2021 was $56.20 billion with a 31% operating margin. First of all, as shown in the table above I forecast product sales out to 2030. writing - trading down slightly from its all-time high of >$160 achieved in early December last year. Disclosure: I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Venclexta - a "first-in-class BCL-2 inhibitor for multiple hematological malignancies", according to Gonzalez, is forecast for strong growth, whilst Gonzalez has name checked 3 new drugs he expects to be approved by 2026. Finally, eye-care - another division inherited from Allergan - has been performing well for AbbVie although I am not expecting particularly strong growth from the current product portfolio. Factset: FactSet Research Systems Inc.2019. Having dived into the numbers however and looked ahead to 2030 through the eyes and guidance of management, my conclusion is that investors can probably buy AbbVie stock at current price with reasonably high hopes of making a decent ROI - perhaps 15 - 20% in the next 12 - 18 months, whilst also benefiting from a generous dividend. It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Gonzalez has vigorously defended AbbVie against accusations of price manipulation, but the company is renowned for pushing drug prices up annually and should its powerful lobbies become less powerful in the face of external pressure, once again, the sector will start to look unattractive for investors. Multidrug Resistant Bacteria Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2030) Published: March 2, 2023 at 2:55 a.m. Compare Top Brokerages Here. Our Product Disclosure Statement (PDS) and Target Market Determination provides important information about our products and who our products are more likely to be suited to Capital.com does not provide financial or investment advice and you should seek independent advice if you are unsure of the risks or whether our products are suitable for you. AbbVie passed that onto its 2022 guidance. Build a CFD portfolio with your favourite companies. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. On average, analysts rate AbbVie stock as a buy. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community. The company also successfully completed the acquisition of Syndesi Therapeutics SA in March. I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. View our ABBV earnings forecast. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. The 21 analysts offering 1 year price forecasts for ABBV have a max estimate of and a min estimate of . AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.83%. All rights reserved. According to CompaniesMarketCap, the biopharmas market capitalisation stood at $272.38bn, making it the worlds 30th most valuable company. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. AbbVie's Dividend and Valuation. The drug is now approved in severe Rheumatoid Arthritis, active Psoriatic Arthritis, moderate to severe Atopic Dermatitis, Ulcerative Colitis, active Ankylosing Spondylitis, with Crohn's Disease the next approval on the list. (NYSE: ABBV) Abbvie's current Earnings Per Share (EPS) is $6.65. Identify stocks that meet your criteria using seven unique stock screeners. While some of the gains are due to investor perception that it is a strong company, some view ABBV as a defensive stock, with most of the other stocks in the sector also doing well. (ABBV) AbbVie Stock Predictions from the Leading Provider of Short and Long Term Stock Price Forecasts. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. Capital Com Australia Pty Ltd (ABN 47 625 601 489) is a company registered in Australia and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL 513393. The consensus among Wall Street research analysts is that investors should "hold" ABBV shares. Please. Currently, the company has a "stable" rating, but that must be maintained or investors will perceive the company as unsafe to invest in and that will drag the share price down rapidly. The lowest target is $136.35 and the highest is $210. My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. Armed with management's detailed guidance and commentary on sales performance of key assets and new product launches, however, I have completed sales projections for AbbVie to 2030, which I will share in this post, highlighting areas of strength and potential weaknesses. Date. AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. (my tables). Neurology also looks strong although aesthetics, eye care and oncology have something to prove. All generate blockbuster <$1bn per annum sales - in Stelara's case >$9bn per annum, and in Enbrel's case, >$4.5bn. I have no business relationship with any company whose stock is mentioned in this article. The company issued revenue guidance of -. Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. AT&T Inc. (T) stock forecast and price target Find the latest AT&T Inc. T analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Specifically, they have bought $0.00 in company stock and sold $23,102,528.00 in company stock. If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. Richard A. Gonzalez has an approval rating of 88% among the company's employees. What that means is, essentially it will be on formulary with biosimilars, but there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX). As we can see, AbbVie is likely to generate some impressive cash flow based on its operating margins, which begin at 32%. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. contact@marketbeat.com It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. 164.71 0.00 0.00%. The company provided earnings per share (EPS) guidance of $10.70- for the period. Rinvoq's progress has been a little more circumspect, but almost as impressive. The most recent increase was . That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive licence to its Humira-related patents in the US, which will begin on 1 July 2023. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! The company has a robust pipeline of new products that are in some stage of clinical trials. The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. What is a Good Dividend Yield? As we can see above one of either Skyrizi or Rinvoq has now been approved for all of the same indications as Humira is, except for Hidradenitis Suppurativa, although Rinvoq is undergoing a Phase study in this indication. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. According to AbbVie CEO Rick Gonzalez, speaking on the Q2'22 earnings call, "Skyrizi's total prescription share of the U.S. biological market (in psoriasis) has increased to approximately 26%", and". Shares are consolidating with a buy. The company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.54 by $0.06.